Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
Pharmacies like Snyders rely on reimbursements to make ends meet. When his business dispenses prescriptions, the repayment ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback